Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 52635N103 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
FMR LLC
13G/A
Amendment 2
|
5.7% |
9/8/2026
Event 8/31/2026
|
|
| FMR LLC | 5.7% | ||
| Abigail P. Johnson | 5.7% | ||
|
Millennium Management LLC
13G
|
5.1% |
6/26/2026
Event 6/23/2026
|
|
| Millennium Management LLC | 5.1% | ||
| Millennium Group Management LLC | 5.1% | ||
| Israel A. Englander | 5.1% | ||
| BlackRock, Inc. 13G | 5.8% |
4/27/2026
Event 3/31/2026
|
|
|
Squarepoint Ops LLC
13G
|
5.1% |
4/8/2026
Event 4/1/2026
|
|
| Squarepoint Ops LLC | 5.1% | ||
| Squarepoint Capital LLP | 5.1% | ||
| Squarepoint Operations Private Limited | 5.1% | ||
| Squarepoint (DIFC) Ltd | 5.1% | ||
| Squarepoint Master Fund Limited | 5.1% | ||
| Squarepoint Core Master Fund Limited | 0% | ||
|
Ridgeback Capital Investments L.P.
13G/A
Amendment 1
|
0% |
2/17/2026
Event 12/31/2025
|
|
| Ridgeback Capital Investments L.P. | 0% | ||
| Ridgeback Capital Investments LLC | 0% | ||
| Ridgeback Capital Management LLC | 0% | ||
|
FMR LLC
13G/A
Amendment 1
|
11.8% |
2/5/2026
Event 12/31/2025
|
|
| FMR LLC | 11.8% | ||
| Abigail P. Johnson | 11.8% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.9% |
1/21/2026
Event 12/31/2025
|
|
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 1
|
3.8% |
11/14/2025
Event 9/30/2025
|
|
| Paradigm BioCapital Advisors LP | 3.8% | ||
| Paradigm BioCapital Advisors GP LLC | 3.8% | ||
| Senai Asefaw, M.D. | 3.8% | ||
| Paradigm BioCapital International Fund Ltd. | 3.3% | ||
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
4.8% |
11/14/2025
Event 9/30/2025
|
|
| Point72 Asset Management, L.P. | 1.2% | ||
| Point72 Capital Advisors, Inc. | 1.2% | ||
| Point72 Biotech Private Investments, LLC | 3.6% | ||
| Differentiated Ventures Investments, LLC | 3.6% | ||
| 72 Investment Holdings, LLC | 3.6% | ||
| Steven A. Cohen | 4.8% | ||
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 9
|
3.4% |
11/10/2025
Event 11/5/2025
|
|
| Versant Venture Capital VI, L.P. | 3.4% | ||
| Versant Ventures VI GP, L.P. | 3.4% | ||
| Versant Ventures VI GP-GP, LLC | 3.4% | ||
| Versant Vantage II, L.P. | 2.7% | ||
| Versant Vantage II GP, L.P. | 2.7% | ||
| Versant Vantage II GP-GP, LLC | 2.7% | ||
| Versant Venture Capital VII, L.P. | 2.7% | ||
| Versant Ventures VII GP, L.P. | 2.7% | ||
| Versant Ventures VII GP-GP, LLC | 2.7% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 2
|
13.6% |
11/7/2025
Event 11/5/2025
|
|
| RA Capital Management, L.P. | 13.6% | ||
| Peter Kolchinsky | 13.6% | ||
| Rajeev Shah | 13.6% | ||
| RA Capital Healthcare Fund, L.P. | 10.8% | ||
|
FMR LLC
13G
|
15.0% |
11/7/2025
Event 10/31/2025
|
|
| FMR LLC | 15.0% | ||
| Abigail P. Johnson | 15.0% | ||
| BlackRock, Inc. 13G | 5.1% |
10/17/2025
Event 9/30/2025
|
|
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 8
|
4.1% |
9/22/2025
Event 9/18/2025
|
|
| Versant Venture Capital VI, L.P. | 4.1% | ||
| Versant Ventures VI GP, L.P. | 4.1% | ||
| Versant Ventures VI GP-GP, LLC | 4.1% | ||
| Versant Vantage II, L.P. | 3.0% | ||
| Versant Vantage II GP, L.P. | 3.0% | ||
| Versant Vantage II GP-GP, LLC | 3.0% | ||
| Versant Venture Capital VII, L.P. | 3.2% | ||
| Versant Ventures VII GP, L.P. | 3.2% | ||
| Versant Ventures VII GP-GP, LLC | 3.2% | ||
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 7
|
4.9% |
8/20/2025
Event 8/18/2025
|
|
| Versant Venture Capital VI, L.P. | 4.9% | ||
| Versant Ventures VI GP, L.P. | 4.9% | ||
| Versant Ventures VI GP-GP, LLC | 4.9% | ||
| Versant Vantage II, L.P. | 3.0% | ||
| Versant Vantage II GP, L.P. | 3.0% | ||
| Versant Vantage II GP-GP, LLC | 3.0% | ||
| Versant Venture Capital VII, L.P. | 3.6% | ||
| Versant Ventures VII GP, L.P. | 3.6% | ||
| Versant Ventures VII GP-GP, LLC | 3.6% | ||
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 6
|
5.6% |
7/14/2025
Event 7/10/2025
|
|
| Versant Venture Capital VI, L.P. | 5.6% | ||
| Versant Ventures VI GP, L.P. | 5.6% | ||
| Versant Ventures VI GP-GP, LLC | 5.6% | ||
| Versant Vantage II, L.P. | 3.0% | ||
| Versant Vantage II GP, L.P. | 3.0% | ||
| Versant Vantage II GP-GP, LLC | 3.0% | ||
| Versant Venture Capital VII, L.P. | 4.0% | ||
| Versant Ventures VII GP, L.P. | 4.0% | ||
| Versant Ventures VII GP-GP, LLC | 4.0% | ||
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 5
|
7.0% |
6/24/2025
Event 6/20/2025
|
|
| Versant Venture Capital VI, L.P. | 7.0% | ||
| Versant Ventures VI GP, L.P. | 7.0% | ||
| Versant Ventures VI GP-GP, LLC | 7.0% | ||
| Versant Vantage II, L.P. | 3.0% | ||
| Versant Vantage II GP, L.P. | 3.0% | ||
| Versant Vantage II GP-GP, LLC | 3.0% | ||
| Versant Venture Capital VII, L.P. | 4.0% | ||
| Versant Ventures VII GP, L.P. | 4.0% | ||
| Versant Ventures VII GP-GP, LLC | 4.0% | ||
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 4
|
7.5% |
6/12/2025
Event 6/10/2025
|
|
| Versant Venture Capital VI, L.P. | 7.5% | ||
| Versant Ventures VI GP, L.P. | 7.5% | ||
| Versant Ventures VI GP-GP, LLC | 7.5% | ||
| Versant Vantage II, L.P. | 3.0% | ||
| Versant Vantage II GP, L.P. | 3.0% | ||
| Versant Vantage II GP-GP, LLC | 3.0% | ||
| Versant Venture Capital VII, L.P. | 4.7% | ||
| Versant Ventures VII GP, L.P. | 4.7% | ||
| Versant Ventures VII GP-GP, LLC | 4.7% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 1
|
15.1% |
5/9/2025
Event 5/7/2025
|
|
| RA Capital Management, L.P. | 15.1% | ||
| Peter Kolchinsky | 15.1% | ||
| Rajeev Shah | 15.1% | ||
| RA Capital Healthcare Fund, L.P. | 12.0% | ||
|
Paradigm Biocapital Advisors LP
13G
|
5.2% |
3/27/2025
Event 3/20/2025
|
|
| Paradigm BioCapital Advisors LP | 5.2% | ||
| Paradigm BioCapital Advisors GP LLC | 5.2% | ||
| Senai Asefaw, M.D. | 5.2% | ||
| Paradigm BioCapital International Fund Ltd. | 4.6% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 1.15 k | $4.40 k |
| 2026 Q2 | 152 | 34.7 M | $198 M |
| 2026 Q1 | 153 | 33.1 M | $303 M |
| 2025 Q4 | 170 | 35.1 M | $562 M |
| 2025 Q3 | 173 | 29.2 M | $1.36 B |
| 2025 Q2 | 122 | 24.8 M | $726 M |
| 2025 Q1 | 106 | 21.1 M | $542 M |
| 2024 Q4 | 96 | 19.9 M | $572 M |
| 2024 Q3 | 80 | 18.7 M | $445 M |
| 2024 Q2 | 68 | 19.0 M | $328 M |
| 2024 Q1 | 60 | 16.3 M | $363 M |